Key Drivers
- Very high gross
- Strong free cash
- Elevated SG&A
AIAI Summary
MiMedx has moved from turnaround speculation to a cash-rich, gross‑margin‑driven business with GAAP profitability and a $100M buyback that establish a durable valuation floor and give management optionality. However, the investment hinges on binary external outcomes—CMS reimbursement and legal rulings—or demonstrable, repeatable surgical revenue/SG&A discipline to justify re-rating, so investors should be tactical and wait for regulatory/legal clarity or consistent margin conversion before taking a meaningful position.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high gross
- •Strong free cash
- •Elevated SG&A
MiMedx delivers very high gross margins, strong cash flow and low leverage but heavy SG&A and operating expenses materially compress net margins despite attractive returns and moderate valuation. #HighSG&A
Price Behavior
Key Price Behavior Insights:
- •Lower highs forming
- •Support breached
- •Oversold bounce possible
MDXG is in a clear short-term downtrend after a ~20% decline last month, breaching prior support near $5.10 (now resistance) and trading down to $4.12 with the $4.36–$4.38 band as minor support—failure below $4.12 would confirm further downside while a recovery above $5.10–$5.30 would signal stabilization.
Sharp ~20% drop from $5.17 to $4.12 over last month indicating rapid weakening
Sentiment & News
Key News Insights:
- •Revenue rebound
- •Share buyback
- •High-volume selling
MiMedx reported strong Q4 and FY sales growth, beat EPS estimates, launched a new product and authorized a $100M buyback but shares plunged to fresh 52-week lows amid heavy selling.
Operational momentum and product expansion improve fundamentals, but ongoing investor selloff and new lows create near-term downside risk for the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings